Ajinomoto Bio-Pharma Services offers two novel, patented microbial expression systems for protein and antibody synthesis.

Developed by Ajinomoto Co., the innovative Corynex® expression system and TALAMAX® expression system offer significant advantages over traditional technologies to provide simplified, fast, scalable, and affordable production of proteins and antibodies.

Corynex® is an innovative platform utilizing gram-positive Corynebacterium glutamicum bacterium for protein production. It greatly simplifies the purification process of complex recombinant proteins and improves your drug development process by reducing production costs and time to market.

Advantages of the Corynex System:

• Endotoxin free and minimal impurities during the manufacturing process, reduces the time needed to produce the bulk drug
• Low cost of goods allows you to minimize production costs
• Highly scalable, which improves the chances of a successful commercial launch
• Successful track record in clinical trials (US FDA)

TALAMAX® is an innovative platform utilizing Talaromyces cellulolyticus in the production of antibodies. It greatly simplifies the production process of aglycosylated antibodies and improves your drug development process by reducing manufacturing costs and time to market.

TALAMAX is ideal for bispecific-antibodies and antibodies for ADCs, since cultivation occurs without glycosylation.

Advantages of the TALAMAX System:

• Endotoxin free and non-toxic
• Fast production time vs. animal cells
• Aglycosylation
• Low risk of immunogenicity by non-mammalian type glycol-chain
• Low risk of side effect by glyco-chain
• Low cost of goods allows you to minimize production costs
• Highly scalable, which improves the chances of a successful commercial launch
• Can also be used to produce IgG-based hard to express fusion proteins